|0.1994||+0.0204||+11.40%||Vol 501.01K||1Y Perf -94.19%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||0.01 2.71%|
|Target Price||18.00||Analyst Rating||Strong Buy 1.00|
|Potential %||8.93K||Finscreener Ranking||★★★★★ 68.22|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 68.59|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★★ 72.34|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||0.68||Earnings Rating||Strong Buy|
|Market Cap||3.51M||Earnings Date||9th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.72|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||245.61K|
|Avg. Monthly Volume||551.93K|
|Avg. Quarterly Volume||468.07K|
Aptevo Therapeutics Inc. (NASDAQ: APVO) stock closed at 0.1994 per share at the end of the most recent trading day (a 11.4% change compared to the prior day closing price) with a volume of 501.01K shares and market capitalization of 3.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Aptevo Therapeutics Inc. CEO is Marvin L. White.
The one-year performance of Aptevo Therapeutics Inc. stock is -94.19%, while year-to-date (YTD) performance is -91.41%. APVO stock has a five-year performance of -91.33%. Its 52-week range is between 0.1517 and 7.2, which gives APVO stock a 52-week price range ratio of 0.68%
Aptevo Therapeutics Inc. currently has a PE ratio of 1.70, a price-to-book (PB) ratio of 0.70, a price-to-sale (PS) ratio of 3.79, a price to cashflow ratio of -, a PEG ratio of -, a ROA of 14.89%, a ROC of 25.59% and a ROE of 58.32%. The company’s profit margin is 99.40%, its EBITDA margin is -354.00%, and its revenue ttm is $3.11 Million , which makes it $0.61 revenue per share.
Of the last four earnings reports from Aptevo Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Aptevo Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aptevo Therapeutics Inc. is Strong Buy (1), with a target price of $18, which is +8 927.08% compared to the current price. The earnings rating for Aptevo Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptevo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptevo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.38, ATR14 : 0.03, CCI20 : -39.14, Chaikin Money Flow : -0.06, MACD : -0.03, Money Flow Index : 50.97, ROC : -14.42, RSI : 39.38, STOCH (14,3) : 43.92, STOCH RSI : 1.00, UO : 47.30, Williams %R : -56.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptevo Therapeutics Inc. in the last 12-months were: Daphne L. Taylor (Option Excercise at a value of $0), Grant Grady (Sold 0 shares of value $0 ), Jeffrey G. Lamothe (Option Excercise at a value of $0), Kunz Barbara (Sold 0 shares of value $0 ), Kwon Soyoung (Sold 0 shares of value $0 ), Lamothe Jeffrey (Sold 0 shares of value $0 ), Marvin L. White (Option Excercise at a value of $0), Niederhuber John (Sold 0 shares of value $0 ), So Young Kwon (Option Excercise at a value of $0)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.